Join to view full profile
600 N Wolfe StBaltimore, MD 21287
Phone+1 410-955-5000
Fax+1 303-724-3889
Dr. Weekes is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Alabama Hospital (Birmingham)Residency, Internal Medicine, 2000 - 2003
University of Nebraska College of MedicineClass of 2000
Certifications & Licensure
MA State Medical License 2017 - 2028
MD State Medical License 2003 - 2025
CO State Medical License 2007 - 2019
AL State Medical License 2001 - 2003
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 15
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
- Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Publications & Presentations
PubMed
- Pancreatic Reirradiation: A Multi-Institutional Retrospective Analysis of Feasibility, Tolerability, and Clinical Outcomes.Helen X Hou, Hannah J Roberts, Priyadarshini S Pathak, Harvey J Mamon, Joseph D Mancias
American Journal of Clinical Oncology. 2026-10-05 - 1 citationsNeoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma.Federico De Stefano, Nathaniel F Wu, Giulio Belfiori, Hannah J Roberts, Cristina Ferrone
JAMA Surgery. 2026-10-01 - Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma.Federico De Stefano, Giulio Belfiori, Nathaniel F Wu, Jill N Allen, Laura Cerri Crn
Annals of Surgery. 2026-09-10
Press Mentions
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic CancerApril 27th, 2026- Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic CancerFebruary 25th, 2025
- Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib plus FOLFIRINOX as First Line Therapy for Advanced Pancreatic CancerFebruary 7th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
